Drugs Affecting Blood and Blood Formation — MCQs
On this page
Which of the following is an antiplatelet drug?
What is the mechanism of action of ticagrelor?
Oral anticoagulants are monitored by what?
Which of the following statements about the oral anticoagulant warfarin is incorrect?
What is the primary mechanism of action of warfarin in a patient with atrial fibrillation?
Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs
Question 361: Which of the following is an antiplatelet drug?
- A. Clopidogrel (Correct Answer)
- B. Streptokinase
- C. Hirudin
- D. Tranexamic acid
Explanation: ***Clopidogrel*** - Clopidogrel is an **antiplatelet agent** that works by irreversibly inhibiting the **P2Y12 ADP receptor** on platelets, preventing platelet activation and aggregation. - It is commonly used for the prevention of **thrombotic events** in patients with acute coronary syndrome, stroke, or peripheral artery disease. *Tranexamic acid* - Tranexamic acid is an **antifibrinolytic drug** that inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. - It is primarily used to **reduce bleeding** in various conditions such as heavy menstrual bleeding, surgical procedures, and trauma. *Streptokinase* - Streptokinase is a **thrombolytic agent** that acts by forming a complex with plasminogen, leading to its conversion to plasmin, which then breaks down fibrin clots. - It is used to dissolve existing blood clots in conditions such as acute myocardial infarction, pulmonary embolism, and deep vein thrombosis. *Hirudin* - Hirudin is a direct **thrombin inhibitor** originally isolated from the salivary glands of medicinal leeches. - It directly binds to and inactivates thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting clot formation.
Question 362: What is the mechanism of action of ticagrelor?
- A. PAR1 activator
- B. P2Y12 inhibitor (Correct Answer)
- C. P2Y12 activator
- D. PAR1 inhibitor
Explanation: ***P2Y12 inhibitor*** - Ticagrelor is an **oral antiplatelet agent** that works by reversibly binding to the **P2Y12 receptor** on platelets. - This binding prevents adenosine diphosphate (ADP) from activating the P2Y12 receptor, which is crucial for **platelet aggregation** and **thrombus formation**. *PAR1 inhibitor* - **PAR1 inhibitors** (e.g., vorapaxar) block the thrombin receptor on platelets, leading to antiplatelet effects. - This mechanism is distinct from ticagrelor's action on the P2Y12 receptor. *PAR1 activator* - Activating **PAR1** would promote platelet aggregation and activation, which is the opposite effect of an antiplatelet medication like ticagrelor. - This mechanism would increase the risk of thrombosis. *P2Y12 activator* - Activating the **P2Y12 receptor** would lead to increased platelet aggregation and is not the mechanism of action for an antiplatelet drug. - Drugs that activate P2Y12 would promote the formation of blood clots.
Question 363: Oral anticoagulants are monitored by what?
- A. Bleeding time (BT) - Assesses platelet function
- B. Coagulation time (CT) - General clotting assessment
- C. Prothrombin time (PT) - Monitors extrinsic pathway (Correct Answer)
- D. Partial thromboplastin time (PTT) - Monitors intrinsic pathway
Explanation: ***Prothrombin time (PT) - Monitors extrinsic pathway*** - **Oral anticoagulants**, such as **warfarin**, inhibit the synthesis of **vitamin K-dependent clotting factors** (II, VII, IX, X), which primarily affect the **extrinsic pathway** of coagulation. - The **PT** measures the time it takes for plasma to clot after the addition of **tissue factor**, assessing the function of the extrinsic and common pathways, making it the standard test for monitoring warfarin therapy. - In clinical practice, **INR (International Normalized Ratio)** is derived from PT to standardize results across laboratories. *Bleeding time (BT) - Assesses platelet function* - **Bleeding time** assesses **platelet function** and **vascular integrity**, not the efficacy of oral anticoagulants. - It is an older test, largely replaced by **platelet function analyzers** and **platelet aggregation studies** for assessing platelet disorders. *Coagulation time (CT) - General clotting assessment* - **Coagulation time** is a general, less sensitive measure of overall clotting and is not specific enough to accurately monitor the effects of oral anticoagulants. - It is a historical test with limited clinical utility for anticoagulant management. *Partial thromboplastin time (PTT) - Monitors intrinsic pathway* - The **partial thromboplastin time (PTT)** assesses the **intrinsic and common pathways** of coagulation, primarily used to monitor **heparin therapy**. - While oral anticoagulants can affect some factors in the intrinsic pathway, the **PT** is the more sensitive and appropriate test for monitoring their effect.
Question 364: Which of the following statements about the oral anticoagulant warfarin is incorrect?
- A. Inhibits vitamin K epoxide reductase
- B. Acts both in vivo and in vitro (Correct Answer)
- C. Acts only in vivo
- D. Causes bleeding complications such as Hematuria
Explanation: ***Acts both in vivo and in vitro*** - This statement is incorrect because **warfarin** is an **oral anticoagulant** that acts **only in vivo** by inhibiting **vitamin K epoxide reductase**, thereby interfering with the synthesis of **vitamin K-dependent clotting factors (II, VII, IX, X)** in the liver [1, 2]. - Its mechanism requires metabolic processing by the body, meaning it has no direct anticoagulant effect on blood samples **in vitro** [1]. *Inhibits vitamin K epoxide reductase* - This statement is correct. **Warfarin's mechanism of action** involves inhibition of **vitamin K epoxide reductase (VKORC1)**, the enzyme responsible for regenerating the reduced form of **vitamin K** [1, 2]. - This prevents the **γ-carboxylation** of glutamate residues on **clotting factors II, VII, IX, and X**, rendering them biologically inactive [2]. *Acts only in vivo* - This statement is correct, as **warfarin's anticoagulant effect** is entirely dependent on its metabolism within the body to interfere with **coagulation factor synthesis** [1]. - It does not exert any direct anticoagulant effect if added to a blood sample in a test tube [1]. *Causes bleeding complications such as Hematuria* - This statement is correct. A common and significant side effect of **warfarin** is an increased risk of bleeding due to its **anticoagulant properties** [1]. - **Hematuria** (blood in the urine) is one of several potential bleeding complications (along with **epistaxis**, **gum bleeding**, or **gastrointestinal bleeding**) that can occur if the **anticoagulation level is excessive** [1].
Question 365: What is the primary mechanism of action of warfarin in a patient with atrial fibrillation?
- A. Inhibition of vitamin K epoxide reductase (Correct Answer)
- B. Inhibition of thrombin
- C. Inhibition of platelet aggregation
- D. Activation of antithrombin III
Explanation: ***Inhibition of vitamin K epoxide reductase*** - **Warfarin** acts as a **vitamin K antagonist**, specifically by inhibiting the enzyme **vitamin K epoxide reductase (VKORC1)**. - This inhibition prevents the regeneration of reduced vitamin K, which is essential for the gamma-carboxylation of clotting factors II, VII, IX, and X, thereby impairing their activation and reducing the blood's ability to clot. *Inhibition of thrombin* - Drugs that directly inhibit thrombin (Factor IIa) are **direct thrombin inhibitors** (DTIs), such as Dabigatran, not Warfarin. - While effective in preventing clot formation, this is a distinct mechanism from Warfarin's action on vitamin K-dependent factors. *Inhibition of platelet aggregation* - **Antiplatelet drugs** like aspirin or clopidogrel inhibit platelet aggregation, which is crucial for primary hemostasis and arterial thrombus formation. - Warfarin's mechanism primarily affects the coagulation cascade (secondary hemostasis), not directly platelet function. *Activation of antithrombin III* - Heparin and related drugs like low molecular weight heparins (LMWH) exert their anticoagulant effect by **potentiating the activity of antithrombin III**. - Antithrombin III then inactivates several clotting factors, including thrombin and factor Xa, which is different from Warfarin's mechanism.
Practice by Chapter
Hematopoietic Growth Factors
Practice Questions
Iron Preparations and Management of Iron Deficiency
Practice Questions
Vitamin B12 and Folic Acid
Practice Questions
Anticoagulants: Heparins and Direct Inhibitors
Practice Questions
Oral Anticoagulants
Practice Questions
Antiplatelet Drugs
Practice Questions
Thrombolytic Agents
Practice Questions
Hemostatic Drugs
Practice Questions
Plasma Expanders
Practice Questions
Blood Transfusion and Alternatives
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free